Preparedness for and response to meningococcal outbreaks: preliminary results of a Canadian Immunization Research Network (CIRN) randomized controlled trial of two schedules of 4CMenB vaccine in adolescents and young adults.
https://www.meningitis.org/mrf-conference-2017
Current situation in the meningitis belt, impact of MenAfriVac, countries that have introduced or committed to introducing it into routine schedules, catch up campaigns, controlling outbreaks and the challenge of maintaining vaccine stockpiles, use of conjugate and polysaccharide vaccines
https://www.meningitis.org/mrf-conference-2017
Prospects for GBS prevention - current candidates & removing barriers to licensure of a GBS vaccine for pregnant women globally
https://www.meningitis.org/mrf-conference-2017
Single-dose oral ciprofloxacin prophylaxis as a meningococcal meningitis outbreak response: results of a cluster-randomized trial
https://www.meningitis.org/mrf-conference-2017
Current situation in the meningitis belt, impact of MenAfriVac, countries that have introduced or committed to introducing it into routine schedules, catch up campaigns, controlling outbreaks and the challenge of maintaining vaccine stockpiles, use of conjugate and polysaccharide vaccines
https://www.meningitis.org/mrf-conference-2017
Prospects for GBS prevention - current candidates & removing barriers to licensure of a GBS vaccine for pregnant women globally
https://www.meningitis.org/mrf-conference-2017
Single-dose oral ciprofloxacin prophylaxis as a meningococcal meningitis outbreak response: results of a cluster-randomized trial
https://www.meningitis.org/mrf-conference-2017
What next for prevention of pneumococcal disease in light of serotype replacement? Is there a pathway to licensure for novel pneumococcal vaccines?
https://www.meningitis.org/mrf-conference-2017
Novartis satellite breakfast session at the Meningitis Research Foundation 2013 conference, Meningitis & Septicaemia in Children & Adults presented by Emeritus Professor Richard Moxon, Dr Jamie Findlow and Dr Simon Nadel
These slides talk about the top few candidates in the COVID-19 vaccine race. There are currently around 200 candidates in R&D, a handful of which has entered clinical trials. The top runners are AstraZeneca, Pfizer, & Moderna.
What next for prevention of pneumococcal disease in light of serotype replacement? Is there a pathway to licensure for novel pneumococcal vaccines?
https://www.meningitis.org/mrf-conference-2017
Novartis satellite breakfast session at the Meningitis Research Foundation 2013 conference, Meningitis & Septicaemia in Children & Adults presented by Emeritus Professor Richard Moxon, Dr Jamie Findlow and Dr Simon Nadel
These slides talk about the top few candidates in the COVID-19 vaccine race. There are currently around 200 candidates in R&D, a handful of which has entered clinical trials. The top runners are AstraZeneca, Pfizer, & Moderna.
Susan Little, MD
Professor of Medicine
Co-Director, AntiViral Research Center
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Potential advantages of booster containing PCV regimen - Professor Shabir MadhiWAidid
This slideset, realized by Professor Shabir Madhi on the occasion of the 11th ISPPD held in Melbourne last April, evaluates the potential advantages of booster containing PCV dosing schedule.
To learn more, visit www.waidid.org!
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...hivlifeinfo
Набор слайдов c рассмотрением важных вопросов об АРТ первого ряда, арв-препаратами пролонгированного действия и схемами АРТ с двумя препаратами, акцент в публикации на роль новых стратегий.
A brief overview of the process of vaccine production, clinical trials, and licensing, along with a summary of the different vaccines platforms and vaccine candidates.
ACEP Policy for Fever Infants and Children Younger than 2 Years of Age in EDSun Yai-Cheng
Clinical Policy for Well-Appearing Infants and Children Younger Than 2 Years of Age Presenting to the Emergency Department With Fever
Ann Emerg Med. 2016;67:625-639
Webinar: Demystifying COVID-19 Vaccine Booster
| Demystifying vaccine booster - when and why?
| Speaker: Dr. Kalaiarasu M Peariasamy.
| More information, please visit: https://clinupcovid.mailerpage.com/resources/r1r5o3-demystifying-covid-19-vaccine-boo
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017
1. Preparedness for and response to meningococcal
outbreaks: preliminary results of a Canadian
Immunization Research Network (CIRN) randomized
controlled trial of two schedules of 4CMenB vaccine in
adolescents and young adults
JM Langley, S Gantt, C Quach,, J Bettinger, SA Halperin, J Mutch,
S McNeil, B. Ward, D. MacKinnon-CameronL Ye, K Marty, D.
Scheifele, J Alcantara and CIRN
Funded by the Canadian Institutes of Health Research and the
Public Health Agency of Canada
2. Rationale
Meningococcus B most common cause of IMD in Canada
Institutional outbreaks are rare (<5% of cases) but create
public health crises
MenB vaccine in Canada:
4CMenB (Bexsero®, GlaxoSmithKline) authorized for
persons 2 months -17 years in Dec 2013
Not part of routine immunization schedule
limited data on safety and immunogenicity in persons
>17 years, or on various dosing schedules
Emergency vaccination programs used for outbreaks
Quebec 2014 for 2 month - 20 year olds
Acadia University 2015
3.
4. Methods
Enrolment in first term of academic year (Sept 2015-
April 2016) over 4 to 6 weeks
Eligibility
17-25 years of age, healthy
attending school
randomized, controlled, observer-blinded trial
Compare safety and immunogenicity of two 4CMenB
vaccination schedules: Accelerated (0, 21 days) vs.
Standard schedule (0, 60 days)
7. Immunogenicity outcomes
Human Serum Bactericidal Titres (hSBA) on days 0,
21, 42, 81,180 using MenB strains 5/99, H44/76
and NZ98/254 (assays using epidemic strains
pending)
Geometric Mean Titers (GMTs)
Reverse Cumulative Distribution graphs
10. Conclusions: RCT of 0,21 vs. 0,60 day
4CMenB schedule in 17-25 year old students
Capacity building for rapid trials: conducted rapidly in 1st term
of academic year at 3 sites, >99% retention at six months
Safety: reactogenicity greater in 4CMenB recipients: injection
site pain in >96%, muscles aches and drowsiness in ~50%
(tolerability outcomes pending)
Immunogenicity: protective titers present in all 4CMenB
recipients 21 days after first dose, sustained in >90 % at Day
180 (hSBA to outbreak strains pending)
An accelerated 4CMenB schedule (0, 21 days) could be used
to control outbreaks in adolescents/young adults